Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks

Description

The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.

Conditions

Overactive Bladder

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks - a Single-center Study

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks

Condition
Overactive Bladder
Intervention / Treatment

-

Contacts and Locations

Maywood

Loyola Medical Center, Maywood, Illinois, United States, 60153

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years, female, ambulatory
  • * OAB symptoms \> 6 months
  • * Voiding frequency \> 8 times in 24 hrs and \> 3 episodes of urgency (grade 3 or 4) without incontinence during 3-day diary at baseline
  • * Self-reported urinary incontinence (\> 3 episodes in the month prior)
  • * UTI \> 3 in last 12 months
  • * A diagnosis of painful bladder syndrome or interstitial cystitis
  • * LUT surgery last 6 months
  • * Drug or non-drug treatment of OAB (previous 60 days) or current meds that affect detrusor activity
  • * On Warfarin
  • * Failure to complete 3-day diary
  • * Aspirin \> 81 mg daily
  • * Gross hematuria
  • * Allergy or sensitivity to aspirin
  • * Subjects taking anti-platelet agents
  • * Inability to swallow capsules

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Loyola University,

Elizabeth Mueller, MD, PRINCIPAL_INVESTIGATOR, Loyola Medical Center

Study Record Dates

2025-02-01